Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin’s lymphoma: 2-year results of a phase 1 trial

已完结 10 由 77 发布于 2025/2/6 14:40:17

DOI:10.1038/s41409-022-01888-z
作者：Zhitao Ying, Yan Xie, Wen Zheng, Weiping Liu, Ningjing Lin, Meifeng Tu, Xiaopei Wang, Lingyan Ping, Lijuan Deng, Chen Zhang, Meng Wu, Feier Feng,
文献类型：期刊论文
补充材料：只需要正文

Springer

Abstract：This study reported 2-year efficacy and safety of relma-cel in Chinese patients with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (B-NHL). In this phase 1 dose-escalating trial, p

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:American Chemical Society (ACS)An Asymmetric Synthesis of a Chiral Sulfone Acid with Concomitant Hydrolysis and Oxidation to Enable the Preparation of a Glucokinase Activator